VTRS · Earnings call · 2026Q2T · Full report
Acquisition / Partnership / Divestiture
Viatris Inc · 2026-08-06 · Importance 40 · Surprise 42 · In source text
Viatris agreed to sell its global product rights for Tyrvaya as part of a strategic shift away from eye care. The transaction is expected to close in the second half of 2026, subject to customary closing conditions. Management said the transaction’s anticipated financial impact is fully reflected in the updated 2026 guidance. Separately, the company is evaluating in-market, accretive business-development assets while maintaining discipline on strategic fit and price.
Key facts
- Agreement reached to divest global product rights for Tyrvaya; transaction expected to close in H2 2026 subject to customary closing conditions
- Viatris is pursuing in-market accretive business development opportunities and continues to receive multiple inbound opportunities regularly
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | negative | probable | — | Agreement reached to divest global product rights for Tyrvaya; transaction expected to close in H2 2026 subject to customary closing… |